Malignant solid neoplasm, MSI-H or dMMR
Revision as of 16:19, 22 March 2018 by Warner-admin (talk | contribs) (Text replacement - "?Variant |limit=10000|format=sum}} variants" to "?Variant |limit=10000|format=sum}} variants")
4 regimens on this page
6 variants on this page
|
Note: this is a new type of page for HemOnc.org, as all other regimen pages (except for cancer of unknown primary) are tissue-specific. The initial drug with tissue-agnostic approval is for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Pembrolizumab monotherapy
Regimen
| Study | Evidence |
|---|---|
| Le et al. 2016 (KEYNOTE-164) | Phase II |
Note: this is the FDA-approved pembrolizumab dose and schedule based on a pooled analysis of 5 non-randomized trials. This is one representative trial.
Immunotherapy
- Adults: Pembrolizumab (Keytruda) 200 mg IV once over 30 minutes on day 1
- Children: Pembrolizumab (Keytruda) 2 mg/kg (maximum dose 200 mg) IV once over 30 minutes on day 1
21-day cycle for up to 2 years
References
- Abstract: Dung T. Le, Takayuki Yoshino, Dirk Jäger, Thierry Andre, Johanna C. Bendell, Ruixue Wang... SoonMo Peter Kang, Minori Koshiji, Luis A. Diaz. KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. J Clin Oncol 2016 abstract TPS787 and abstract TPS3631; NCT02460198 at ClinicalTrials.gov